83 Viral co-infections in SARS-CoV-2 4 We then performed a logistic regression analysis to investigate the odds of receiving IMV (Figure 2a) and in-hospital mortality (Figure 2b) for different variables. The odds of receiving IMV are higher for patients with an influenza co-infection compared to those with a SARS-CoV-2 mono-infection whereas this was not observed for people with RSV or adenovirus co-infection. Co-infection with either adenovirus or influenza was associated with increased odds of in-hospital mortality. Age (years) Sex Number of comorbidities 4C Mortality score Co−infection Treatment with steroids Days since start pandemic [18.0,107.0] Female Male [0.0,12.0] [0.0,21.0] no co−infection Adeno co−infection influenza co−infection RSV co−infection No Yes [0.0,730.0] 0.93 (0.92−0.93, p<0.001) − 0.99 (0.85−1.15, p=0.871) 0.70 (0.65−0.75, p<0.001) 1.35 (1.31−1.39, p<0.001) − 1.35 (0.79−2.20, p=0.251) 1.80 (1.22−2.63, p=0.003) 1.06 (0.68−1.60, p=0.794) − 2.41 (1.99−2.92, p<0.001) 1.00 (1.00−1.00, p<0.001) −0.50 −0.25 0.00 0.25 0.50 as.numeric(OR) 1.0 1.5 2.0 2.5 3.0 Odds ratio, 95% CI Invasive Mechanical Ventilation OR (95% CI, p−value) Age (years) Sex Number of comorbidities 4C Mortality score Co−infection Treatment with steroids Days since start pandemic [18.0,107.0] Female Male [0.0,12.0] [0.0,21.0] no co−infection Adeno co−infection influenza co−infection RSV co−infection No Yes [0.0,730.0] 1.01 (1.00−1.02, p=0.001) − 0.98 (0.85−1.12, p=0.741) 1.02 (0.97−1.08, p=0.410) 1.25 (1.22−1.29, p<0.001) − 1.74 (1.11−2.69, p=0.014) 1.61 (1.12−2.30, p=0.009) 1.31 (0.91−1.87, p=0.145) − 2.19 (1.86−2.58, p<0.001) 1.00 (1.00−1.00, p<0.001) −0.50 −0.25 0.00 0.25 0.50 as.numeric(OR) 1.0 1.5 2.0 2.5 Odds ratio, 95% CI Mortality OR (95% CI, p−value) a) Multivariable logistic regression model with IMV as the outcome variable b) Multivariable logistic regression model with in-hospital mortality as the outcome variable. Figure 2: Multivariable logistic regression model Treatment with systemic corticosteroids included treatment with dexamethasone, hydrocortisone, prednisolone, prednisone or methylprednisolone. Only includes patients hospitalised after the release of the RECOVERY trial who also needed supplemental oxygen
RkJQdWJsaXNoZXIy MTk4NDMw